| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |